Inanovate Spotlight
Inanovate completes testing and benchmarking of Bio-ID. Bio-ID Technology Review
The Bio-ID lowers the cost and improves the accuracy of diagnostic tests by rapidly and precisely measuring the concentration of multiple disease related biological molecules (biomarkers) from patient blood samples.
The Bio-ID consists of a compact bench-top analyzer and disposable test cartridges. The end-user simply loads test samples into a Bio-ID cartridge, inserts the cartridge into the analyzer, hits the ‘go’ button and walks away.”
Inanovate’s Mission
“ENABLE ACCESS TO THE DIAGNOSTIC POWER OF THE PROTEOME”
Revolutionized by a novel, proprietary, highly multiplexed serological analyzer platform which enables accurate detection and analysis of complex protein signatures
To achieve this mission, Inanovate has developed a revolutionary technology for the detection and measurement of multiple proteins called Longitudinal Assay Screening (LAS). First developed in 2010, LAS has since been integrated into Inanovate’s first product – The Bio-ID.
The Bio-ID is a new category of protein screening technology that can play a key role in the development and implementation of next generation of diagnostics and therapeutics.
Our History
In 2010 Inanovate begun the development of a novel approach to the detection and measurement of multiple proteins called Longitudinal Assay Screening (LAS). LAS was developed to help users in both research and clinical markets to accurately detect and measure multiple proteins from patient samples at virtually any concentration, without the need for multiple sample dilutions or complex preparations. Recently, Inanovate successfully completed testing and benchmarking the first platform to integrate LAS: The Bio-ID.